Lab
Mercy Health - West Hospital LLC
Mercy Health - West Hospital LLC was paid $2.31M by Medicaid between Jul 2022 and Dec 2024, across 138 billing codes. Its largest line is 87801, Infectious agent detection by nucleic acid; amplified probe, multiple organisms — 9.4% of everything it billed.
33Billing provider infoMERCY HEALTH - WEST HOSPITAL LLC
CINCINNATI, OH 45211
CINCINNATI, OH 45211
33aNPI1982728036assigned 03/16/2007
33bProvider typeClinical Medical Laboratory
28Total paid$2.31M
24GClaims291,416
24DCodes billed138
24AFirst – last monthJul 2022 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Ohio
Rank by total paid#32 of 116
Median peer was paid$313K
This provider vs. median7.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RALSTON, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2022 | 1,974 | $10K | |
| 2023 | 152,456 | $1.07M | |
| 2024incomplete | 136,986 | $1.24M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 9.4% | 5,753 | 5,218 | $217K |
| 80053 | Comprehensive metabolic panel | 8.3% | 24,065 | 21,239 | $191K |
| 84443 | Thyroid stimulating hormone (TSH) | 7.4% | 18,679 | 16,265 | $171K |
| 80061 | Lipid panel | 6.2% | 20,198 | 17,470 | $143K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.5% | 21,043 | 18,291 | $105K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 4.4% | 8,256 | 6,811 | $101K |
| 36415 | Collection of venous blood by venipuncture | 3.6% | 30,108 | 25,139 | $83K |
| 83036 | Hemoglobin; glycosylated (A1C) | 3.0% | 16,085 | 13,712 | $69K |
| 87390 | 2.8% | 4,775 | 4,016 | $65K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.2% | 1,479 | 1,310 | $50K |
| 87480 | 1.9% | 3,885 | 3,560 | $44K | |
| 87660 | 1.8% | 3,886 | 3,561 | $41K |
126 more codes
| 86702 | 1.7% | 4,766 | $39K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.7% | 5,987 | $39K |
| 82607 | 1.6% | 5,564 | $38K | |
| 87510 | 1.6% | 3,886 | $38K | |
| 86701 | 1.5% | 4,772 | $34K | |
| 86803 | 1.4% | 4,114 | $33K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.4% | 771 | $32K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.3% | 4,487 | $30K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 1.3% | 2,036 | $30K |
| 84439 | 1.2% | 4,439 | $28K | |
| 82728 | 1.1% | 3,011 | $25K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 1.0% | 1,179 | $24K |
| 87563 | 1.0% | 1,144 | $24K | |
| 86780 | <1% | 2,825 | $23K | |
| 85027 | <1% | 5,123 | $22K | |
| 84403 | <1% | 1,502 | $22K | |
| 84153 | <1% | 2,024 | $22K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 818 | $20K |
| 82746 | <1% | 4,447 | $20K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 836 | $19K |
| 83550 | <1% | 3,807 | $18K | |
| 81514 | <1% | 295 | $18K | |
| 83540 | <1% | 3,946 | $17K | |
| 84270 | <1% | 1,208 | $16K | |
| 86480 | <1% | 537 | $16K | |
| 82570 | <1% | 3,958 | $16K | |
| 83880 | <1% | 724 | $14K | |
| 83001 | <1% | 1,165 | $14K | |
| 87522 | Neg quan hep c or qual rna | <1% | 892 | $12K |
| 87340 | <1% | 1,702 | $12K | |
| 82043 | <1% | 3,336 | $12K | |
| 83970 | <1% | 551 | $12K | |
| 84146 | <1% | 958 | $11K | |
| 87481 | <1% | 1,056 | $11K | |
| 87077 | <1% | 1,759 | $11K | |
| 86038 | <1% | 1,152 | $10K | |
| 80069 | <1% | 1,580 | $10K | |
| 87070 | <1% | 1,478 | $10K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 457 | $10K |
| 87186 | <1% | 1,658 | $9K | |
| 80076 | <1% | 1,639 | $9K | |
| 83735 | <1% | 2,004 | $8K | |
| 84702 | <1% | 895 | $8K | |
| 86762 | <1% | 931 | $8K | |
| 86850 | <1% | 840 | $8K | |
| 86140 | <1% | 1,787 | $8K | |
| 86696 | <1% | 743 | $7K | |
| 80050 | General health panel | <1% | 1,265 | $7K |
| 86706 | <1% | 879 | $7K | |
| 81001 | <1% | 2,481 | $6K | |
| 86787 | <1% | 715 | $6K | |
| 87808 | <1% | 875 | $6K | |
| 84481 | <1% | 642 | $6K | |
| 83002 | <1% | 538 | $6K | |
| 85652 | <1% | 2,550 | $5K | |
| 82670 | <1% | 319 | $5K | |
| 83516 | <1% | 639 | $5K | |
| 86695 | <1% | 664 | $5K | |
| 80074 | <1% | 351 | $4K | |
| 86431 | <1% | 835 | $4K | |
| 84703 | <1% | 679 | $4K | |
| 87088 | <1% | 635 | $3K | |
| 85610 | <1% | 1,151 | $3K | |
| 84550 | <1% | 979 | $3K | |
| 82627 | <1% | 235 | $3K | |
| 83690 | <1% | 732 | $3K | |
| 87081 | <1% | 551 | $3K | |
| 86900 | <1% | 876 | $3K | |
| 82533 | <1% | 257 | $3K | |
| 84144 | <1% | 247 | $3K | |
| 86901 | <1% | 876 | $3K | |
| 86003 | <1% | 54 | $3K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 123 | $3K |
| 86376 | <1% | 303 | $3K | |
| 82784 | <1% | 365 | $3K | |
| 84425 | <1% | 207 | $2K | |
| 86200 | <1% | 257 | $2K | |
| 82550 | <1% | 493 | $2K | |
| 82950 | <1% | 510 | $2K | |
| 84156 | <1% | 757 | $2K | |
| 84480 | <1% | 230 | $2K | |
| 86694 | <1% | 180 | $2K | |
| 83721 | <1% | 505 | $2K | |
| 82248 | <1% | 431 | $2K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 31 | $2K |
| 81003 | <1% | 739 | $2K | |
| 87205 | <1% | 423 | $1K | |
| 86735 | <1% | 159 | $1K | |
| 86765 | <1% | 162 | $1K | |
| 83013 | <1% | 29 | $1K | |
| 85730 | <1% | 496 | $855.03 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 65 | $833.60 |
| 84590 | <1% | 113 | $782.28 | |
| 83525 | <1% | 102 | $727.39 | |
| 86235 | <1% | 18 | $645.96 | |
| 84446 | <1% | 75 | $568.80 | |
| 84100 | <1% | 180 | $517.61 | |
| 82785 | <1% | 56 | $512.49 | |
| 84460 | <1% | 174 | $512.10 | |
| 87641 | <1% | 13 | $417.08 | |
| 86800 | <1% | 43 | $387.78 | |
| 84165 | <1% | 63 | $364.97 | |
| 84466 | <1% | 54 | $358.75 | |
| 85379 | <1% | 64 | $349.45 | |
| 82565 | <1% | 121 | $348.97 | |
| 86708 | <1% | 47 | $315.80 | |
| 86318 | <1% | 31 | $304.14 | |
| 82985 | <1% | 31 | $291.46 | |
| 82671 | <1% | 15 | $270.38 | |
| 86592 | <1% | 26 | $264.88 | |
| 87075 | <1% | 47 | $261.50 | |
| 84450 | <1% | 95 | $257.09 | |
| 82951 | <1% | 24 | $241.68 | |
| 83883 | <1% | 20 | $218.46 | |
| 86039 | <1% | 36 | $216.70 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 19 | $213.48 |
| 84630 | <1% | 15 | $189.05 | |
| 84155 | <1% | 64 | $161.28 | |
| 86704 | <1% | 27 | $150.87 | |
| 86225 | <1% | 18 | $142.24 | |
| 85045 | <1% | 53 | $123.18 | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 215 | $115.19 |
| 82952 | <1% | 24 | $113.49 | |
| 82947 | <1% | 12 | $75.14 | |
| 83615 | <1% | 18 | $58.88 | |
| 81015 | <1% | 12 | $47.89 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRALSTON, KIMBERLY (SYSTEM DIRECTOR)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.